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Objectives: There is significant room for improvement in the development of tissue-engineered blood vessels (TEBVs) for
vascular reconstruction. Most commonly, TEBVs are seeded with endothelial cells (ECs) only. This provides an antithrom-
bogenic surface but suboptimal physiologic characteristics compared with native arteries, due to lack of smooth muscle cells
(SMCs) in the vessel media. Although SMCs are critical in vessel architecture and function throughout the vascular tree, few
studies have incorporated SMCs in TEBVs implanted in vivo. As such, the goal of the present study was to evaluate the effect
of SMC coseeding with ECs on TEBV maturation, structure, and function after prolonged in vivo maturation.
Methods: Dual-seeded TEBVs (dsTEBVs) were created by coseeding autologous ECs derived from circulating progenitor
cells and SMCs from artery explants onto the lumen and outer surface of extracellular matrix scaffolds, respectively.
Control vessels were seeded with ECs alone (ecTEBV). All vessels were preconditioned to pulsatile flow for 10 to 14 days
in a bioreactor, implanted as arterial interposition grafts in sheep, and allowed to heal and adapt in vivo for 4 months
before ex vivo physiologic testing and histologic analysis.
Results: All implants were patent at 4 months. There were no structural failures, aneurysms, or infectious complications.
The dsTEBVs exhibited a greater degree of wall maturation, characterized by higher medial cellularity (P  .01) and
greater percentage of -actin (P .005) and SMC-specific muscle myosin heavy chain (P .005) staining compared with
ecTEBVs. Contractile responses to phenylephrine and serotonin were significantly greater in isolated rings of dsTEBVs
than those observed in ecTEBVs (P  .01).
Conclusions: To our knowledge, this is the first study that demonstrates enhanced in vivo wall maturation and contractile
function of TEBVs coseeded with autologous SMCs and ECs compared with EC seeding alone. These data suggest a
coseeding strategy can be accomplished in a clinically relevant timeframe (typically 6 weeks) and may provide advantages
for arterial reconstruction compared with vessels engineered only with endothelium. (J Vasc Surg 2011;53:426-34.)
Clinical Relevance: Bioengineering of functional blood vessels using autologous cells has been proposed as an alternative to
prosthetic grafts for patients who lack suitable vein. Previous studies have focused on attaching endothelial cells to the luminal
wall of prosthetic or tissue-engineered vessels. However, vascular smoothmuscle cells (SMCs), which comprise the bulk of the
artery wall, are essential in regulating artery wall geometry, tone, and integrity in response to a variety of hemodynamic and
biochemical stimuli. Therefore, the addition of an SMC layer to an engineered blood vessel would enhance its function. This
study evaluated the effect of incorporating vascular SMCs and endothelium into an engineered blood vessel thatwas implanted
for 4months in vivo. All vessels remained patent andmaintained stable wall geometry without significant stenosis, dilation, or
rupture. Dual-seeded vessels demonstrated enhanced structure and function with greater numbers of cells expressing SMC
markers in the medial layer and significantly improved vasomotor responses than did vessels seeded with endothelium alone.
This strategy may soon evolve into a clinically useful alternative for patients lacking vein for vascular reconstructions.
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Volume 53, Number 2 Neff et al 427In situations where autologous vein is not available or is
inadequate for clinical use as a vascular graft, the primary
alternatives are prosthetic grafts such as Dacron and poly-
tetrafluoroethylene. Although prosthetic grafts function
well as conduits for reconstruction of large-diameter ves-
sels,1 they are susceptible to stenosis, thrombosis, and
occlusion, particularly in diameters 6 mm or when con-
nected to very small-caliber vessels such as coronary and
tibial arteries. All prosthetic grafts also carry the risk of
infection, with the need for subsequent graft excision.2,3
To address these shortcomings, autologous vascular grafts
bioengineered using a patient’s cells have been proposed as
an alternative to current prosthetic materials when suitable
vein is not available.4-9
The concept of engineering tissue using selective cell
transplantation has been applied clinically for a variety of
disorders, including the use of engineered skin, tracheal
constructs, urinary bladder, and grafts for dialysis ac-
cess.10-13 We have previously shown that tissue-engineered
blood vessels (TEBVs) constructed with endothelial pro-
genitor cell-derived endothelial cells (ECs) seeded onto
decellularized arterial scaffolds can be used for carotid
artery reconstruction in an ovine model.14 In that study,
TEBVs remained patent for 4 months and demonstrated
cellular in-growth into the scaffold wall. Although the
presence of a confluent EC monolayer on the luminal
surface prolonged patency compared with unseeded con-
trol grafts, the contractile response of these grafts in vitro
was still significantly less than the native artery, presumably
due to a deficit of functional smoothmuscle cells (SMCs) in
the media.14
In fact, SMCs comprise the bulk of the artery wall,
where they are important in the maintenance of vessel
architecture and mechanical properties as well as in modu-
lating vascular tone in response to a variety of mechanical
and biochemical stimuli.15-17 Therefore, incorporating a
SMC layer into a TEBV should enhance the function of the
reconstructed artery. In this regard, we have recently devel-
oped methods to enhance SMC seeding of arterial scaffolds
coseeded with ECs and demonstrated that bioreactor pre-
conditioning accelerated the formation of the muscular
layer on decellularized scaffolds, and furthermore, that this
muscular layer was capable of mobilizing calcium in re-
sponse to cellular depolarization.18 Others have also docu-
mented contractile responses after SMC seeding of TEBVs
in vitro,9,14,18,19 but we are aware of only one report
demonstrating contractile responses after implantation and
maturation in vivo, and in that report there was no detect-
able impact of 1 month of implantation in vivo on the
observed contractile responses in vitro.19
The goal of the present study was to evaluate the effect
of coseeding of SMCs with ECs on TEBV structure and
function after implantation in vivo. We hypothesized that
not only would the addition of SMCs to the TEBV confer
a more native artery-like phenotype but perhaps the pres-
ence of SMCs would also accelerate maturation, including
gain of vasomotor function of the implanted TEBV. Con-
sistent with this supposition, coseeding SMCs enhanced repopulation of the media by cells expressing SMCmarkers
nd resulted in significantly increased contractile responses
ompared with vessels seeded only with ECs at 4 months
fter arterial reconstruction in an ovine arterial interposi-
ion model.
ATERIALS AND METHODS
All animal procedures in this study were approved by
he Wake Forest University Animal Care and Use Commit-
ee in compliance with accepted standards.20
Isolation and characterization of autologous SMCs
nd ECs. Female Dorper Cross sheep (aged 4 to 12
onths) were purchased fromRSI Farms (Mocksville, NC)
nd fed a standard diet (Rumilab, PMI, St. Louis, Mo).
ndothelial progenitor cells were isolated from blood of anes-
hetized sheep using an affinity-based pheresis system to cap-
ure CD133 cells, as previously described.21 Briefly, 1800
L of blood was cycled through an extracorporeal circuit
ontaining a CD133-affinity column, between the femoral
rtery and vein. Bound CD133 endothelial progenitor
ells were eluted from the column with trypsin and cul-
ured on fibronectin-coated plates in endothelial growth
edia (EGM-2, Cambrex, East Rutherford, NJ), as de-
cribed.21,22 Media was changed at 5 and 8 days. After 10
ays, colonies emerged that were expanded and character-
zed for typical growth and morphology. Expression of
C-specific markers (von Willebrand factor, vascular endo-
helial growth factor 2, endothelial nitric oxide synthase,
nd Ulex-Lectin) in cells derived with this system have
ecently been extensively characterized.21
Autologous SMCs were cultured from a 3-cm section
f femoral artery that was excised during the endothelial
rogenitor cell isolation procedure for each animal in the
tudy. These artery segments were stripped of adventitia
nd opened longitudinally to denude the endothelium by
entle scraping. Pieces were cut to about 1 mm2, and
ttached to culture dishes, and then incubated in Dulbecco
odified Eagle’s Medium with low glucose, L-glutamine,
nd 10% fetal bovine serum (Cambrex, East Rutherford,
J), as previously described.18 Migrated SMCs were pas-
aged and expanded for graft seeding with ECs from the
ame animal.
Scaffold preparation. Decellularized porcine arterial
egments were prepared as previously described.14,18 Briefly,
ommoncarotid arterial segmentswith an internal diameter of
to 5 mmwere harvested fresh, cut to length, and washed in
eionized water for 48 hours. Vessel segments were then
ncubated in 0.05% trypsin-ethylenediaminetetraacetic acid
Gibco, Invitrogen, Carlsbad, Calif) for 1 hour, followed
y incubation in decellularization solution (490 mL dis-
illed water, 10 mL Triton-100X, 3.4 mL ammonium
ydroxide) for 3 days in a rotating shaker at 4°C. Decellu-
arized extracellular matrix scaffolds were washed in deion-
zed water for an additional 48 hours, frozen for 24 hours at
80°C, lyophilized, and sterilized with ethylene oxide.
mmediately before seeding, scaffolds were rehydrated
vernight in sterile phosphate-buffered saline (PBS) then
insed with PBS before seeding.
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February 2011428 Neff et alScaffold seeding and preconditioning. To construct
the TEBVs, ECs and SMCs were trypsinized and resus-
pended in media at a density of 2  106 and 5  105
cells/mL, respectively. Scaffolds were mounted into a
closed bioreactor with the lumen gently perfused with an
EC suspension. For dual-seeded TEBVs (dsTEBVs), the
SMC suspension was introduced into an outer chamber
surrounding the scaffold. Scaffolds were rotated at 10 rpm
for 2 hours at 37°C without fluid flow in the lumen. Flow
was then initiated using a computer-operated gear pump
(Ismatec, Glattbrugg, Switzerland) controlled by a custom
LabVIEW program (National Instruments Corp, Austin,
Tex) to flow EGM-2 through the lumen. Bioreactor pre-
conditioning consisted of graded increases in lumen flow
rate and shear stress, with a transition from steady to
pulsatile flow 5 days after seeding, simulating arterial he-
modynamic conditions (shear stress was 9.9 dynes/cm2
during diastole and 13.2 dynes/cm2 during systole), as
previously described.18,22 This resulted in a biphasic pulse
pressure wave without reversal of flow in diastole.18 Pulsa-
tile flow (60 cycles/min) was continued to at least day 10
with graft implantation from days 10 to 14.
TEBV implantation. Each animal (n  5 per group)
received a TEBV produced from its own cells. Animals were
given clopidogrel bisulfate (75 mg) and aspirin (325 mg)
orally 1 day before and daily for 7 days after surgery. Two
animals in each group had undergone prior carotid artery
procedures, so the TEBVs were implanted as femoral inter-
position grafts, whereas all other grafts were implanted as
common carotid artery interposition grafts. Consistent
with the relative similarities in the hemodynamic environ-
ment and structural characteristics of these two vessels, our
preliminary observations did not reveal any obvious differ-
ences in the salient characteristics of the retrieved vessels
evaluated. As such, we considered all grafts to represent a
homogeneous population for purposes of statistical analysis
for these initial studies.
Under general anesthesia, the target artery was exposed
and controlled with vessel loops. Heparin was administered
(100 U/kg, i.v.) and vessel loops were secured before a
5-cm length of artery was excised. The TEBV (6-cm long)
was sutured end-to-end as interposition graft using running
6-0 polypropylene suture. Incisions were closed in two
layers with absorbable suture. After the animals were recov-
ered, they were returned to standard housing until the
TEBVs were explanted 4 months later.
TEBV patency and geometry. After implantation,
the bioengineered vessels were examined by palpation three
times per week and monthly by duplex ultrasound imaging
(Sequoia, Acuson Inc, Mountain View, Calif). Midgraft
cross-sectional diameter and Doppler velocity waveforms
were assessed in the native artery, across anastomoses, and
in the mid-TEBV to qualitatively exclude stenoses. Repre-
sentative animals also underwent digital subtraction an-
giography imaging at the time of necropsy.
Histology. The TEBVs were explanted under general
anesthesia. Animals received heparin, the TEBV was re-
moved and rinsed with PBS, and rings were then cut from phe midgraft for physiologic testing. The remaining mid-
raft was fixed by formalin perfusion and three 5-mm rings
ere cut from each and embedded in paraffin for histologic
nalysis. Adjacent sections were cut from each ring and
tained with hematoxylin and eosin (H&E) and Movat
tains or were processed for immunohistochemistry. Anti-
odies specific for -actin (1:500; Millipore, Billerica,
ass) and a myosin heavy chain (MHC) isoform, previ-
usly reported23 to distinguish arterial SMCs from fibro-
lasts/myofibroblasts (1:500; clone BT-562, Biomedical
echnologies, Stoughton, Mass, after antigen retrieval in
eated citrate buffer, pH 6.0) were applied to sections as
reviously described.23,24 Primary antibodies were localized
ith biotinylated secondary antibody (1:400; VectorLabs,
arion, Iowa) after blocking in 5% horse serum (Gibco),
ollowed by the ABC reaction (Vectastain Elite, VectorLabs)
ith diaminobenzidine as the chromogen (Sigma, St.
ouis, Mo).
Sections were viewed with standard light microscopy,
nd medial cell density was determined by averaging nu-
lei/high power field (original magnification 400) in 4
uadrants of each cross-section using a predetermined al-
orithm of centering the field equidistant between internal
nd external elastic laminas at 12, 3, 6, and 9 o’clock.
imilarly, adjacent cross-sections from each ring were
tained for -actin andMHC, and the number of positively
tained cells was quantified using the same algorithm used
or total cell numbers.
Physiologic testing. Rings from the center of each
EBV were cut into three equal 2.5-mm segments, and
ings of similar dimensions were cut from the contralateral
ommon carotid or femoral artery as an intra-animal refer-
nce vessel. Each ring was placed in an organ bath (Rad-
oti, Monrovia, Calif) containing standard Krebs-Ringers
olution continuously bubbled with 95%O2 and 5%CO2 at
7°C to obtain a pH of 7.4, and mounted on stainless steel
ooks connected to a force transducer (ADI Instruments,
olorado Springs, Colo), as previously described.25 Tissues
ere equilibrated at a basal tension of 1.0 g (Lmax) and
onstant length for 30 minutes. Maximal steady-state con-
ractions were then elicited by adding KCl (60mM; general
epolarization of the cell membrane), phenylephrine
10 M; 1-adrenergic agonist), and 5-hydroxytryptamine
5-HT; 10 M; 5-HT2 agonist) to each ring. Isometric
ontractions were recorded using a PowerLab data acqui-
ition unit and analyzed by Chart5 software (AD Instru-
ents, Colorado Springs, Colo).
Statistical analysis. Group-wise comparisons be-
ween the dsTEBVs and ecTEBVs were made for cell
ensity, SMCmarkers, and physiologic parameters using an
npaired t test with significance set at  .05. All statistical
nalysis was performed using GraphPad Prism 4.0 software
GraphPad, La Jolla, Calif).
ESULTS
Decellularized scaffolds averaged a 5 mm inner diame-
er and 6 cm in length at implantation after bioreactor
reconditioning (Fig 1, A). Preimplantation histology
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Volume 53, Number 2 Neff et al 429demonstrated multiple layers of SMCs on the outer wall,
with minimal penetration of the scaffold wall (Fig 1, B). A
luminal endothelial monolayer was also present, with a
paucity of underlying SMCs (Fig 1, A, C). Grafts demon-
strated easy handling, solid suture retention, rapid hemo-
stasis at the suture line, and no transgraft bleeding, despite
the use of antiplatelet agents and heparin (Fig 1, D). All
grafts (n  5 per group) were patent at 4 months after
implantation when removed for ex vivo analysis (Fig 1, E).
No grafts demonstrated significant stenosis, aneurysm/
pseudoaneurysm, or thrombosis by duplex imaging (not
shown), angiography (Fig 1, E), or upon examination ex
vivo. All grafts were well incorporated at the time of ex-
plant, without purulence or acute inflammation. One graft
from the ecTEBV group was not suitable for physiologic
studies due to extensive vessel wall calcification.
Histologic analysis. Three main findings document
that dsTEBVs exhibited a greater degree of tissue matura-
tion than ecTEBVs. First, as illustrated in Fig 2, dsTEBVs
displayed greater overall graft cellularity (3806 	 175
cells/mm2 vs 2835 	 325 cells/mm2, P  .01) than
ecTEBVs.
Second, the percentage of cells in the TEBV wall that
stained positive for -actin and smooth muscle MHC was
much higher in the dsTEBV group than in the ecTEBV
Fig 1. A, Hematoxylin and eosin (H&E) histology (original
magnification 100) of a preimplant dual-seeded tissue-
engineered blood vessel (TEBV) reveals an endothelial monolayer
(bottom) and multilayered smooth muscle cells (SMCs) on the
extraluminal surface (top). Scale bar  400 m. Inset H&E histo-
logic images of the (B) SMC layers (arrowhead) and (C) the
endothelial monolayer (arrow) (original magnification400; scale
bar  100 m). D, Operative photograph of TEBV implantation
as an interposition graft of the common carotid artery, denoted as
A on the top and bottom of the panel. Anastomotic suture lines are
noted (arrows). E, A representative anterior-posterior subtraction
angiography view of an implanted TEBV at 4 months after implan-
tation. Examination of the proximal and distal anastomoses (ar-
rows) demonstrates a slight narrowing due to the small luminal size
discrepancy between the native vessel and TEBV.group (Fig 3). A summary of these data and the corre- dponding statistical conclusions are graphically depicted in
ig 4.
Third, from a qualitative perspective, it was interesting
o note that compared with the dsTEBVs, the ecTEBVs
emonstrated cells primarily in the outer portions of the
ings, suggesting that the cells infiltrating the scaffold wall
ost likely migrated from the extraluminal side inward.
Finally, a Movat stain is included that shows elastic
caffold components, illustrating the internal and external
lastic lamellae of the scaffolds and the paucity of neointima
n these midgraft segments (Fig 2).
Physiologic studies in vitro evaluating contractile
unction. Pharmacologic studies were conducted to de-
ermine the maximal amplitude of the steady-state con-
ractile responses observed on retrieved dsTEBVs and
cTEBVs to the physiologically relevant spasmogens, phen-
lephrine and 5-HT, as well as in response to depolarization
ith KCl. Representative examples of the responses to
henylephrine and 5-HT are shown in Fig 5, with mean
alues for all experiments shown in Fig 6. As illustrated, the
aximal amplitude of the phenylephrine- and 5-HT-
nduced contractile responses in the dsTEBVs were signifi-
antly larger than those observed for ecTEBVs. Specifically,
he mean values for the maximal phenylephrine-induced
ontractile responses were 0.27 	 0.03 g (n  17) for
sTEBVs and 0.16 	 0.02 g (n  13) for ecTEBVs (P 
01). The corresponding values for 5-HT were 0.54 	
.08 g (n  17) for dsTEBVs and 0.25 	 0.02 g (n  13)
or ecTEBVs (P  .01). However, statistically significant
ifferences in contractile response were not seen with stim-
lation by KCl, where the corresponding values for
sTEBVs were 0.15 	 0.02 g (n  13) and 0.15 	 0.01 g
n  13; Fig 6).
The values for contraction reported for the ecTEBVs
re similar to a previous report.14 However, despite the
nhanced contractility of the dsTEBV grafts over the
cTEBV grafts, the maximal contractile response seen with
henylephrine and 5-HTwas still only about 15% to 20% of
hat observed for the corresponding responses of the native
rtery from these same animals, which were 1.4 	 0.2 g
n  24) for phenylephrine and 4.1 	 0.7 g (n  24) for
-HT. Similarly, the KCl-induced maximal contractile re-
ponse of the normal contralateral native carotid artery was
.6 	 0.4 g (n  24).
ISCUSSION
A truly functional engineered blood vessel has been
alled “The Holy Grail of Peripheral Vascular Surgery.”26
atients without suitable vein have few options for
edium- to small-diameter arterial bypass procedures.
rosthetic grafts perform poorly in these situations,
rompting the search for alternatives.27 Recent advances in
issue engineering have culminated in clinical pilot studies
f blood vessels seeded with autologous cells for arterial
econstruction and for AV grafts.4,8,13,14,19,28-30 Although
ther groups have constructed TEBVs with various sup-
orting cell types, including SMC, cells like SMCs, adipose-
erived stem cells, and fibroblasts, there is very little evi-
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February 2011430 Neff et aldence that in vivo maturation results in a functional medial
SMC layer.8,13,14,19,29-32 In the present study, we demon-
strated that SMC seeding and preconditioning resulted in a
TEBVwith enhanced contractile responses to relevant ago-
nists after in vivo maturation. Contractile function in
dsTEBVs was associated with increased medial cell density
and with an increase in the fraction of cells expressing
SMC-specific markers compared with grafts seeded only
with ECs.
From a clinical perspective, limited graft patency is a
major problem. Several factors contribute to graft occlu-
sion, including acute thrombosis and anastomotic intimal
hyperplasia.33-35 The role of ECs in preventing thrombosis
has been well documented.33,34,36,37 A functional endo-
thelium may also limit SMC proliferation and intimal hy-
perplasia as well as promote vasodilation. Also important to
clinical application is having conduit available in a wide
range of sizes on short notice. In the present study we
attempted to construct vessels in a clinically relevant time
frame of about 6 weeks to implantation. The relatively brief
period of culture after seeding of the scaffold (10 to 14
days) was adequate to achieve a confluent endothelium14
but limited the mass of SMCs present at implantation.
Fig 2. Representative images (original magnification 
dual-seeded tissue-engineered blood vessel (dsTEBV), an
4 months in vivo stained with (A, E, I) Movat, (B, F,
(D, H, L) smooth muscle cell (SMC) myosin heavy cha
fibers that define the internal and external elastic lamella
(F) dsTEBV compared with the (J) ecTEBV on H&E
positive for (G vs K) -actin and (H vs L) MHC. ScaleImprovements in scaffold design and cell isolation and Seeding could further shorten time to implantation, but
ngineering conduits for emergency applications will re-
uire different approaches than those used here.
Creating a truly functional vessel will also require com-
lex integration of endothelium and an SMC layer respon-
ive to biochemical and hemodynamic cues. Bioengineer-
ng blood vessels with SMCs presents a significant
hallenge in achieving relevant numbers of cells in a brief
eriod of time.13 Conversely, vessels implanted with too
ew SMCs may fail to repopulate adequately secondary to
MC senescence or attrition during graft wall healing and
aturation. To facilitate SMC adaptation and potentially
urvival on implantation, we used a preconditioning proto-
ol to mimic arterial pressure and strain. From our previous
xperiments,18 we found that this allows SMCs to accumu-
ate and lay down new extracellular matrix before implan-
ation and likely prepares them for the stress-strain in vivo
fter implantation. Despite the relatively small number of
MCs present on grafts at implantation (Fig 1, A and B)
hey were associated with extensive repopulation of the
edia compared with the limited cellularity of grafts seeded
nly with ECs (Figs 2-4).
These data clearly indicate that the presence of the
of (A, B, C, D) native artery control, the (E, F, G, H)
J, K, L) endothelial cell-seeded TEBV (ecTEBV) after
ematoxylin and eosin (H&E), (C, G, K) -actin, and
HC). Representative images demonstrate (E, I) elastin
e TEBV scaffold and increased overall cellularity of the
ogy as well as increased immunohistochemical staining
400 m.100)
d (I,
J) h
in (M
e of th
histolMCs contributes to medial healing, but further studies
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Volume 53, Number 2 Neff et al 431using labeled SMCs that can be tracked over time would be
required to confirm a direct contribution from seeded cells
vs enhanced in-growth of new host-derived SMCs or their
progenitors. Our observation of in-growth of host cells into
the implanted graft is consistent with prior studies involv-
Fig 3. Representative images (original magnification
dual-seeded tissue-engineered blood vessel (TEBV), and
in vivo stained with (A, D, G) hematoxylin and eosin (H
(MHC). Representative images demonstrate increased o
(G) the EC-seeded vessel on H&E and eosin histolog
positive for (E vs H) -actin and (F vs I) MHC. Scale b
Fig 4. Graphic comparison and statistical summary of percentage
of cells with positive immunohistochemical staining in themedia of
the dual-seeded tissue-engineered blood vessel (dsTEBV ) grafts
and the endothelial cell-seeded TEBV (ecTEBV ) grafts. As illus-
trated, the dsTEBVs revealed a greater percentage of cells in the
TEBVwall that stained positive for -actin andmyosin heavy chain
(MHC) compared with the ecTEBVs. The error bars show the
standard error of the mean.ing engineered vascular tissue.8,13,14,19,29-32 eSome cells in the TEBV wall that exhibited morpho-
ogic features consistent with SMCs as well as -actin
taining, were also negative for the presence of the SMC-
pecific marker (MHC). These cells likely represent the
resence of myofibroblasts.19,29 We documented a greater
raction of cells that expressed both -actin and smooth
uscleMHC in dsTEBVs, but less overlap was noted in the
cTEBV group. This observation leads us to believe that
erhaps the host cellular infiltrate responsible for the phys-
ologic response in ecTEBVs was partly compromised by
he presence of myofibroblasts. Although some groups
ave preferentially used fibroblasts to construct TEBVs,13
broblasts are not likely to produce the same degree of
unctionality obtained with SMCs or SMC progenitors,
articularly for applications in medium and small arteries
here vasomotor responses are more important than for
arge-conduit arteries. However, directly comparing con-
ractile responses in vessels constructed with fibroblasts vs
MCs would be required to define the potential of each cell
ype to produce physiologic responses after maturation in
ivo.
We have previously shown that SMC seeding of decel-
ularized scaffolds can be enhanced by removing the adven-
itial layer before seeding the outer graft wall.18 In initial in
itro experiments, we tried seeding SMCs inside the graft,
s in previous studies, using porous polytetrafluoroethyl-
) of (A, B, C) native artery control, the (D, E, F)
, I) endothelial cell (EC)-seeded TEBV after 4 months
), (B, E, H) -actin, and (C, F, I) myosin heavy chain
cellularity of (D) the dual-seeded vessel compared with
ell as increased immunohistochemical staining that is
100 m.400
(G, H
&E
verall
y as wne.38 However, the SMCs did not migrate into the inner
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February 2011432 Neff et alscaffold wall but instead formed a neointima. We were thus
concerned about intimal thickening and stenosis if we
implanted such grafts, so we altered seeding, placing SMCs
on the outer graft and reported that removing the adven-
titia promoted cell accumulation and penetration of the
outer wall without weakening the scaffold significantly.18
Combining preconditioning to pressure and flow fur-
ther enhanced development of a muscular coat compared
Fig 5. Representative tracings of pharmacologic respo
(dsTEBV) and (B, D) endothelial cell-seeded TEBV in re
M phenylephrine. The arrows indicate the application o
Fig 6. Summary graph of the increased steady-state maximal
contractile response that was observed in the dual-seeded tissue-
engineered blood vessel (dsTEBV) relative to the endothelial cell-
seeded TEBV (ecTEBV) in response to stimulation of the 1-
adrenergic receptor subtype with phenylephrine (10 M; P .01)
and the 5-hyroxytryptamine 2 (5-HT) receptor subtype with 5-HT
(10 M; P  .01). No significant difference was observed in the
mean maximal contractile response to potassium chloride (KCl)
between the two TEBV treatment groups (n  a mean of 3 rings
per TEBV implanted). Error bars show the standard error of the
mean.with grafts seeded under static conditions. In those studies, nhe resulting vascular constructs demonstrated a physio-
ogic response to depolarization with KCl (ie, intracellular
alcium mobilization) in vitro.18 However, no receptor-
ediated calcium mobilization response was seen with the
ddition of phenylephrine or 5-HT. These previous obser-
ations create an interesting phenotypic difference relative
o our current observations. The current study has demon-
trated that not only do TEBVs develop contractile re-
ponses to these particular agonists when allowed tomature
n vivo for 4 months (ie, using the body as the final
ioreactor/incubator) but that SMC seeding is also associ-
ted with increased TEBV wall cellularity and increased
ontractile responses compared with grafts seeded only
ith ECs (Figs 5 and 6).
Potential limitations. Despite 4 months of matura-
ion in vivo, we observed that TEBVs produced only a
raction of the contractile response seen in native vessels (eg
5% to 20% of carotid artery). There may be several reasons
or this. First, cells that exhibited an SMC phenotype from
he histologic and morphologic perspective, may have an
ltered receptor density, distribution, and/or subtype and,
hereby, incomplete/altered cell signaling and excitation-
ontraction coupling relative to native artery media. That
s, perhaps not all of the cells in the vessel wall are capable of
ontributing to the agonist-induced contractile responses.
n addition, using a single time point limited our under-
tanding of whether wall function was improving, stable, or
erhaps deteriorating over time. Additional studies will be
ecessary to focus on the timing of the functional changes
hat occur in the TEBV wall over time.
Another limitation of our study design is that cells were
f (A, C) dual-seeded tissue-engineered blood vessels
se to (A, B) 10 M5-hydroxytryptamine and (C, D) 10
nists.nse o
sponot labeled and monitored over time to ensure that ob-
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Volume 53, Number 2 Neff et al 433served differences between groups were from a direct effect
of seeded cells or an indirect effect of having cells present at
implantation but perhaps not direct repopulation of the
TEBV wall by seeded cells. There are data in the literature
to support a direct contribution from seeded SMCs in the
ovine model,30 whereas other investigators postulate an
indirect benefit from preseeding scaffolds with cells that
affects subsequent immune response.31 Further experi-
ments will be necessary to address the underlying mecha-
nism.
Although our technique for EC isolation can be made
minimally invasive for clinical applications, isolating SMCs
from artery biopsy specimens is impractical for patients.
Alternative strategies to obtain large numbers of SMC
precursors in a shorter time frame will be necessary, ideally
from circulating progenitors.
Finally, although we did not see any evidence for aneu-
rysmal degeneration or stenoses, validating this approach in
other preclinical models will be desirable before clinical
trials.
CONCLUSIONS
In earlier studies, we demonstrated methods for the
optimization of the in vitro preconditioning of tissue engi-
neered vascular grafts that contain SMCs. The current
study demonstrates that incorporating SMCs on the out-
side of a TEBV wall combined with preconditioning to
arterial hemodynamics was associated with increased pop-
ulation of the TEBV wall by SMCs in a large-animal model
of arterial reconstruction. Moreover, SMC seeding con-
ferred a corresponding greater physiologic response to
receptor-mediated agonists compared with TEBVs seeded
with ECs only. Further studies are needed to define
whether vessels allowed to mature for longer periods of
time in vivo will become even more functionally and histo-
logically similar to native blood vessels.
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